Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGNETICAL: CMR Evaluation of Tafamidis in Cardiac Transthyretin Amyloidosis
2021-003158-21Phase 4Active
- Sponsor
- ULS Trás-os-Montes e Alto Douro
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tafamidis in transthyretin amyloidosis (ATTR), hereditary transthyretin amyloidosis (hATTR) and amyloid cardiomyopathy, sponsored by ULS Trás-os-Montes e Alto Douro. Primary endpoint: Change in CMR imaging parameters. Started Nov 2022; status: active.
02
Drugs
tafamidis
03
Conditions
transthyretin amyloidosis (ATTR)hereditary transthyretin amyloidosis (hATTR)amyloid cardiomyopathy
Beyond the preview
Go deeper on 2021-003158-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003158-21.